BioCentury
ARTICLE | Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

September 1, 2017 9:35 PM UTC

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Thursday in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush and Chardan.

The company was spun out of the University of Oxford in 2014 with £12 ($19.8 million) in a series A round from Syncona Partners. The company has exclusive, worldwide rights to NSR-REP1 (AAV2-REP1) from the lab of Oxford professor and Nightstar co-founder Robert MacLaren...